A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. | LitMetric

AI Article Synopsis

  • Sildenafil citrate (Revatio) is approved for pediatric pulmonary arterial hypertension (PAH) in the EU, with a new 10 mg/mL oral suspension specifically developed for this purpose.
  • A study involving 42 healthy adults tested the bioequivalence of this new suspension against the commercial 20-mg Revatio tablet and 10-mg clinical trial tablets using a 3-way crossover design.
  • Results showed that all three formulations were bioequivalent at a 20-mg dose, as confirmed by the statistical analysis of pharmacokinetic parameters and were well tolerated by participants.

Article Abstract

Sildenafil citrate (Revatio) is approved for pediatric pulmonary arterial hypertension (PAH) in the European Union. A new pediatric formulation, 10 mg/mL sildenafil citrate powder for oral suspension (POS), was developed for pediatric PAH patients. Bioequivalence among the POS suspension (20 mg), the Revatio 20-mg commercial tablet, and the sildenafil citrate 2 × 10-mg clinical trial tablets was assessed. In this randomized, open-label study, 42 healthy adult volunteers received the 3 different sildenafil treatments, each in a single 20-mg oral dose, using a 3-way crossover design. Blood samples were collected at predefined times and analyzed for sildenafil plasma concentrations. Natural log-transformed sildenafil pharmacokinetic parameters (Cmax , AUClast , and AUC∞ ) were evaluated for bioequivalence using a mixed-effects model. Results were used to estimate relative bioavailability and construct 90% confidence intervals (CIs). Bioequivalence was concluded if the 90% CIs for Cmax , AUClast , and AUC∞ were wholly contained within 80% to 125%. All 90% CIs for the ratios of adjusted geometric means of Cmax , AUClast , and AUC∞ were within 80% to 125%, the prespecified bioequivalence criteria. All 3 formulations were well tolerated. In conclusion, the POS suspension, the commercial 20-mg Revatio tablet, and the 10-mg sildenafil tablets were all bioequivalent to one another when given at the equal doses.

Download full-text PDF

Source
http://dx.doi.org/10.1177/2160763X12455172DOI Listing

Publication Analysis

Top Keywords

sildenafil citrate
12
cmax auclast
12
auclast auc∞
12
randomized open-label
8
3-way crossover
8
sildenafil
8
powder oral
8
oral suspension
8
pulmonary arterial
8
arterial hypertension
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!